MaxCyte Acquires SeQure Dx
Summary
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a Rockville, MD-based cell-engineering focused company, announced the acquisition of SeQure Dx, a Waltham, MA-based market leader of on-target and off-target editing assessment services for cell and gene therapies. Under the terms of the agreement, Maxcyte paid a total initial consideration of $4.5 million at closing in cash for the entire issued share capital of SeQure DX on a cash free, debt free basis using Maxcyte’s existing cash resources. This strategic acquisition strengthens MaxCyte’s ability to serve ex vivo and in vivo cell and gene therapy (CGT) developers with an innovative suite of tools and services spanning early R&D through clinical development and commercialization. It provides comprehensive off-target risk assessment solutions for gene editing, spanning from early discovery through IND submission. Led by CEO Maher Masoud, MaxCyte is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of new cell therapeutics.